Innovent Biologics Inc. (1801:HK) (IVBXF) PT Raised to HK$1,101 at Credit Suisse
Tweet
Share
E-mailGet Alerts 1801:HK Hot Sheet
Price: $0.00 --0%
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 20 | New: 68
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 20 | New: 68
Trade Now!
Join SI Premium – FREE
Credit Suisse analyst Yang Huang raised the price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF) to HK$1,101.00 (from HK$120.00) while maintaining a Outperform rating.
You May Also Be Interested In
- SJM Holdings Ltd (880:HK) (SJMHY) PT Lowered to HK$11 at CLSA
- Teck Resources Ltd (TECK-B:CN) (TECK) PT Raised to Cdn$32 at Scotiabank
- Wynn Macau Ltd. (1128:HK) (WYNMY) PT Raised to HK$16.80 at CLSA
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Intl RatingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
